MarketPulse

duvakitug

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva, Blackstone Life Sciences Team Up on $400M Deal for GI Drug duvakitug

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.
SNYTEVAmonoclonal antibodyclinical development
BenzingaBenzinga··Vandana Singh

Teva and Sanofi Report Positive Phase 3 Results for Duvakitug IBD Treatment

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.
SNYTEVAmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi and Teva Report Sustained Efficacy for Duvakitug in IBD Maintenance Study

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease